Neuropathic Pain / Other Treatments Lecture Flashcards
What are the classifications of low back pain in the 2017 guidelines?
Acute: <4 weeks.
Subacute: 4–12 weeks.
Chronic: >12 weeks.
Recommendations for acute/subacute LBP?
non-pharm preferred : Heat/massage/acupuncture/spinal manipulation
If medications are required – NSAIDs and/or skeletal muscle relaxants
Treatment recommendations for chronic LBP?
1st line: non-pharm options: exercise/mindfulness practices/yoga/tai chi/biofeedback/ cognitive behavioral treatment/spinal manipulation
If there is a poor response consider pharmacotherapy in this order:
1) NSAIDs
2) tramadol or duloxetine
3) opioids (only after risks/benefits are weighed)
negative aspects of muscle relaxants?
CNS depression (dizziness, confusion, coordination)
Dependence (avoid combo w/ alcohol, benzos, opioids)
Withdrawal (potentially life-threatening in severe cases)
what are first line agents for neuropathic pain?
Gabapentin - affects descending noradrenergic and sertonergic pain transmission pathways
Amitriptyline - inhibition of serotonin and/or norepinephrine in CNS
SNRIs - (Duloxetine & Venlafaxine) - ^^
What are common side effects of neuropathic pain medications?
Gabapentin/Pregabalin: Sedation, GI upset.
TCAs: potentially fatal arrhythmias, sedation
SNRIs: Suicidal ideation (1st 2–4 weeks), headache, sedation
what are third/fourth line agents for neuropathic pain?
cannabis
botox
opioids
SSRIs
in the endocannabinoid system - what’s the difference between CB1 and CB2 receptors?
CB1 = CNS. Mood, motor tone, cognition, peripheral nervous system (visceral sensation)
CB2 = periphery. cellular & humoral response to neuroinflammation and pain
What are the key components of medical cannabis?
THC: Partial CB1/CB2 agonist → muscle relaxation, sedation, analgesia.
CBD: CB1/CB2 antagonist → fewer analgesic effects, modulates other systems (5HT, TRPV)
What are the pros and cons of smoked cannabis for pain?
Pros: May improve subjective symptoms (pain, stiffness, relaxation).
Cons: Insufficient evidence for safety/effectiveness in MS-related spasticity or fibromyalgia